Adrian Kilcoyne
Chief Medical Officer Cellectis
Adrian Kilcoyne, M.D., MPH, MBA was appointed Cellectis’ Chief Medical Officer in August 2024. Before joining Cellectis, he served as Chief Medical Officer and Head of Research and Development at Celularity, advancing oncology allogeneic CAR-T and NK cell therapy programs, and previously was Chief Medical Officer at Humanigen. He has held oncology leadership roles across Research and Development, Medical Affairs, Commercial, and Health Economic Outcome Research at companies including AstraZeneca and Celgene. He graduated from Trinity College Dublin Medical School and trained in Gynecological Oncology, Public Health Medicine at Oxford, pharmaceutical medicine, and completed an MBA.
Seminars
Thursday 17th September 2026
Setting the Benchmark for Efficacy & Safety in CAR-T Therapy
12:25 pm
- Learnings on dual CAR-T design, why targeting CD20xCD22 simultaneously
- Rationale for NHL indication
- Present the eti-cel preliminary data
Wednesday 16th September 2026
Industry Leader’s Fireside Chat: Evaluating the CAR & TCR Therapeutic & Commercial Landscape to Propel Advanced Cell Therapy Innovation, Expand Treatment Options & Ensure Positive Commercial Outcomes
8:20 am
- Highlighting evolving modality innovations and industry shifts to demonstrate how rapid scientific and technological progress is enhancing treatment accessibility and reshaping the cell therapy landscape
- Aligning clinical development, scalability and patient access strategies to accelerate commercialization pathways across advanced cell therapy modalities
- Discussing post-approval reimbursement policies and strategies to ensure long-term commercial success
- Predicting cell therapy evolution through 2026 and beyond to provide strategic and commercial foresight
